Our findings also showed that the hyperactivated PLOD2-DCLK1-L axis in ccRCC is correlated with a higher EMT signature and predicts an unfavorable prognosis in ccRCC patients, while disrupting this signaling by pharmacological targeting of DCLK1-L significantly attenuated cancer malignancy both in vitro and in vivo. The gene discussed is DCLK1; the disease is nonpapillary renal cell carcinoma.